ライフサイエンスコーパス: rehospitalization

1 ined endpoint of mortality and heart failure rehospitalization).

2 at multivariable analysis for mortality and rehospitalizations).

3 ggest strategies for intervention to prevent rehospitalization.

4 n, chronic rejection, cancer, infection, and rehospitalization.

5 ge hospital rankings for 30-day mortality or rehospitalization.

6 rankings for 30-day all-cause mortality and rehospitalization.

7 e 9-item version (PHQ-9) to predict death or rehospitalization.

8 st-MI angina and long-term risk of unplanned rehospitalization.

9 wer 30-day mortality, but had similar 30-day rehospitalization.

10 alized patients, and factors associated with rehospitalization.

11 es the association between ICD treatment and rehospitalization.

12 associated with the greatest hazard of early rehospitalization.

13 o (MOR) for in-hospital mortality and 30-day rehospitalization.

14 ng hospital discharge and the probability of rehospitalization.

15 ion rates have intensified efforts to reduce rehospitalization.

16 OR = 1.69; P = 0.032), but no HCE for 30-day rehospitalization.

17 tinuous care and adverse outcomes, including rehospitalization.

18 nces, patients would rather avoid death than rehospitalization.

19 arly associated with reduced risk for 30-day rehospitalization.

20 97) were associated with the highest risk of rehospitalization.

21 pact on all-cause mortality and the need for rehospitalization.

22 ) is associated with lower risk of death and rehospitalization.

23 of PVR on 1-year mortality and heart failure rehospitalization.

24 mortality, length of stay, and costs during rehospitalization.

25 the composite of all-cause mortality and HF rehospitalization.

26 e may adversely affect their outcomes during rehospitalization.

27 ignificant effect on short-term mortality or rehospitalization.

28 nical ventilation are at high risk for early rehospitalization.

29 atients was 7.6% for early and 4.6% for late rehospitalizations.

30 patients who are at high risk for unplanned rehospitalizations.

31 dex, may allow hospitals to reduce unplanned rehospitalizations.

32 post-AMI and followed them for mortality and rehospitalizations.

33 ial infarction, post-discharge ED visits, or rehospitalizations.

34 ngs, yielding harms that include unnecessary rehospitalizations.

35 ed; the relationship was unclear in 27.2% of rehospitalizations.

36 Angiography was performed in 153 (23.8%) rehospitalizations.

37 was performed to determine the cause of all rehospitalizations.

38 .5) when compared with patients without such rehospitalizations.

39 nctional status may help to reduce unplanned rehospitalizations.

40 Over one quarter of all rehospitalizations (28.6% for early; 26.7% for late) inv

41 95% confidence interval, 0.82-0.95), 6-month rehospitalization (36.3% in 2006, 33.7% in 2010; adjuste

42 al cardiovascular events (4.5% versus 4.5%), rehospitalization (43% versus 49%), emergency department

43 ively) but lower 1-year unadjusted all-cause rehospitalization (54.7% versus 62.5% versus 60.0% versu

44 to predict the risk of HF and cardiovascular rehospitalization 60 days after hospitalization for acut

45 The majority of unplanned rehospitalizations (72%) were for cardiovascular reasons

46 ignificantly associated with 30-day death or rehospitalization (adjusted odds ratio, 0.95 [95% CI, 0.

47 tive, any unplanned inpatient or observation rehospitalization after acute myocardial infarction repr

48 ent negative predictor of combined death and rehospitalization after adjustment for age, left ventric

49 and have individually been found to predict rehospitalization after admission for acute heart failur

50 n to better predict patients at low risk for rehospitalization after admission for acute HF.

51 response improves risk prediction for early rehospitalization after an admission for acute HF and ma

52 We sought to determine the frequency of rehospitalization after an ICU stay, outcomes for rehosp

53 Limited data suggest high rates of unplanned rehospitalization after endovascular and surgical revasc

54 nd resource use but information on unplanned rehospitalization after injury admissions is scarce.

55 Early rehospitalization after kidney transplantation (KTx) is

56 pact of patient age on the risks of death or rehospitalization after primary prevention implantable c

57 Rehospitalizations after acute myocardial infarction for

58 ission rates, causes, and costs of unplanned rehospitalizations after peripheral arterial revasculari

59 ease, an intensive care unit admission, or a rehospitalization (all P </= .04) compared with those wh

60 individual- and hospital-level predictors of rehospitalization among individuals with advanced cancer

61 brillators (ICD) and all-cause mortality and rehospitalization among patients undergoing initial ICD

62 eding, repeat coronary procedures, death, or rehospitalization) among patients in these studies who w

63 to determine the independent risk of 30-day rehospitalization and 1-year mortality, respectively.

64 in uninvolved communities, all-cause 30-day rehospitalization and all-cause hospitalization declined

65 ntervention on the composite end point of HF rehospitalization and cardiac death in this population.

66 rease or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect

67 reate a comprehensive dataset for mortality, rehospitalization and kidney allograft failure/rejection

68 rden, with high rates of early postdischarge rehospitalization and mortality.

69 oor and is associated with increased risk of rehospitalization and mortality.

70 antial association between regional rates of rehospitalization and overall admission rates.

71 to assess factors associated with unplanned rehospitalization and tested for interactions among angi

72 Risk of rehospitalization and treatment failure (defined as psyc

73 e databases were linked to study the risk of rehospitalization and treatment failure from July 1, 200

74 that improve functional outcomes and prevent rehospitalizations and adverse events is a high priority

75 vers at hospital discharge lead to increased rehospitalizations and decreased quality of health care.

76 CI, 1.09-4.84) even after adjusting for both rehospitalizations and emergency department visits betwe

77 The number of rehospitalizations and emergency department visits were

78 when properly implemented may help reduce HF rehospitalizations and include adopting a mechanistic ap

79 e common, the overall fiscal impact of these rehospitalizations and their variability between hospita

80 ts receiving aliskiren (77 CV deaths, 153 HF rehospitalizations) and 26.5% of patients receiving plac

81 r the aliskiren group (126 CV deaths, 212 HF rehospitalizations) and 37.3% for the placebo group (137

82 ncluding need for renal replacement therapy, rehospitalization, and death, according to the incidence

83 tential HCE for length of stay (LOS), 30-day rehospitalization, and in-hospital mortality, adjusting

84 ization, patient characteristics, treatment, rehospitalization, and mortality within the Veterans Aff

85 s associated with decreased quality of life, rehospitalization, and mortality.

86 e implantation, long-term survival, cost per rehospitalization, and utility associated with patients'

87 cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow

88 Early unplanned rehospitalizations are common after acute myocardial inf

89 ients with heart failure (HF), use of 30-day rehospitalization as a healthcare metric and increased p

90 These results have implications for using rehospitalization as a measure of quality of care.

91 imary outcomes were defined as mortality and rehospitalization as a result of HF.

92 icare FFS beneficiaries and all-cause 30-day rehospitalizations as a percentage of hospital discharge

93 as no change in the rate of all-cause 30-day rehospitalizations as a percentage of hospital discharge

94 Mean community-wide rates of rehospitalizations as a percentage of hospital discharge

95 t, the adjusted HR for myocardial infarction rehospitalization associated with DES use was significan

96 rall freedom from death, transplantation, or rehospitalization at 1 year following admission was 21%.

97 th increased risk of death and heart failure rehospitalization at 1 year.

98 ificant differences in the rates of death or rehospitalization at 2 days (same-day discharge, 0.37% [

99 not associated with death alone and death or rehospitalization at 30 days.

100 Cardiovascular death or HF rehospitalization at 6 months and 12 months.

101 andard therapy did not reduce CV death or HF rehospitalization at 6 months or 12 months after dischar

102 -$2,877.88; P = 0.005), whereas survivors of rehospitalization at a different hospital had a modest i

103 We measured frequency of rehospitalization at a different hospital, mortality, le

104 the medical claims forms and records for all rehospitalizations at 233 US hospitals within 1 year of

105 The estimated 1-year rate of rehospitalization because of heart failure was 22.8%, si

106 outcome was the cumulative incidence of late rehospitalization (between 31 and 180 d).

107 atients had higher adjusted 1-year all-cause rehospitalization (black: adjusted odds ratio, 1.28 [95%

108 y associated with greater risks of death and rehospitalization, but similar risks of procedural compl

109 le improved targeting of programs to prevent rehospitalizations, but obtaining such information direc

110 nificantly reduced the risk of mortality and rehospitalization caused by HF.

111 number of rehospitalizations caused by respiratory problems, preva

112 End points were time to death or rehospitalization (combined primary), heart failure symp

113 e mortality, myocardial infarction (MI), and rehospitalization compared with a conservative invasive

114 associated with substantially lower risk of rehospitalization compared with equivalent oral formulat

115 gardless of age, women have a higher risk of rehospitalization compared with men over the first year

116 lemented but is not associated with death or rehospitalization compared with overnight observation.

117 ienced adverse clinical outcomes of death or rehospitalization compared with those who remained free

118 y in patients hospitalized with HF, rates of rehospitalization continue to rise, and approach 30% wit

119 ardial infarction, unstable angina requiring rehospitalization, coronary revascularization (>/=30 day

120 2,653 ICU patients, 79,960 had a first early rehospitalization (cumulative incidence, 16.2%) and an a

121 idence, 16.2%) and an additional 73,250 late rehospitalizations (cumulative incidence, 18.9%).

122 timated sex differences in the daily risk of rehospitalization/death 1 year after discharge from a po

123 dverse outcomes, the median time to death or rehospitalization did not differ significantly between t

124 ive incidence of cerebrovascular events, and rehospitalization due to cardiac reasons and acute heart

125 ve comparable mortality, MACCE, and rates of rehospitalization due to cardiac reasons at 1 year.

126 s, cardiac arrest, myocardial infarction, or rehospitalization due to unstable or progressive angina)

127 p between WHF and the composite end point of rehospitalization, emergency room visits for HF, and mor

128 ents receiving placebo (85 CV deaths, 166 HF rehospitalizations) experienced the primary end point at

129 especified outcomes at 30 days were death or rehospitalization for any reason; death or rehospitaliza

130 tality (P=0.002) and cardiovascular death or rehospitalization for cardiovascular causes (P=0.001).

131 r rehospitalization for any reason; death or rehospitalization for cardiovascular or renal reasons; a

132 d points were all-cause death, nonfatal AMI, rehospitalization for evaluation of possible AMI, and co

133 ere associated with death alone and death or rehospitalization for heart failure (all tests, P<0.0001

134 ssociated with an increased risk of death or rehospitalization for heart failure (hazard ratio [HR],

135 6-1.17; P=0.270), and all-cause mortality or rehospitalization for heart failure (hazard ratio, 1.00;

136 ) and the combined endpoint of mortality and rehospitalization for heart failure (hazard ratio: 1.19

137 crease in overall or cardiovascular death or rehospitalization for heart failure after a mean follow-

138 Variables associated with mortality or rehospitalization for heart failure after multivariate a

139 evated resting heart rate is associated with rehospitalization for heart failure and is a modifiable

140 ecreased (7.1% to 5.0%, p < 0.0001), whereas rehospitalization for heart failure at 30 days increased

141 and 1 year (0.9% versus 4.5%; P=0.02) and of rehospitalization for heart failure from randomization t

142 analysis, independent predictors of death or rehospitalization for heart failure included IMR >40 (HR

143 The rate of rehospitalization for heart failure or death from any ca

144 Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 d

145 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged p

146 failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ven

147 ion were associated with 30-day mortality or rehospitalization for heart failure.

148 e primary end point was the rate of death or rehospitalization for heart failure.

149 ary intervention, is predictive of death and rehospitalization for heart failure.

150 Clinical outcomes included mortality and rehospitalization for heart failure.

151 t was a composite of all-cause mortality and rehospitalization for HF at 18 months.

152 The incidence of death or rehospitalization for HF at 24 weeks was 6%, 31%, and 30

153 moconcentration had a markedly lower risk of rehospitalization for HF in PROTECT (multivariable HR, 0

154 ffects of prolonged anakinra on peak Vo2 and rehospitalization for HF.

155 Similar results were found for rehospitalization for MI (cumulative incidence, 3.4% vs.

156 ated with a lower risk for cardiac death and rehospitalization for MI compared with a conservative in

157 Risk for cardiac death or rehospitalization for MI within 60 days of hospitalizati

158 Rehospitalization for myocardial infarction at 1 year oc

159 se or the composite of death from any cause, rehospitalization for myocardial infarction, or stent th

160 The composite of death from any cause, rehospitalization for myocardial infarction, or stent th

161 psis hospitalization that is not present for rehospitalization for nonsepsis diagnoses.

162 Less surfactant-treated infants needed rehospitalization for respiratory problems after dischar

163 between those who did and did not experience rehospitalization for UA or revascularization using a hi

164 fined as cardiac death, death, reinfarction, rehospitalization for unstable angina, repeat coronary r

165 er treated medically in the RYGB group and 2 rehospitalizations for dehydration in the LAGB group.

166 ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34

167 Previous studies have linked frequent rehospitalizations for heart failure (HF) and increased

168 Preventing rehospitalizations for patients with serious chronic ill

169 Rehospitalizations for recurrent congestion portend poor

170 e summary scores were worse in patients with rehospitalizations for UA (mean difference, -10.1; 95% c

171 irst year after acute myocardial infarction, rehospitalizations for UA and unplanned revascularizatio

172 od clinical outcomes, including decreases in rehospitalization, functional improvements, and favorabl

173 resents a significant event; these unplanned rehospitalizations have not been well characterized.

174 ence interval, 0.60-0.92) and less all-cause rehospitalization (hazard ratio, 0.87; confidence interv

175 .04-1.09; P<0.001, respectively), as well as rehospitalization (hazard ratio, 1.07; confidence interv

176 s, women had a persistent 26% higher risk of rehospitalization (hazard ratio, 1.26; 95% confidence in

177 was most strongly associated with unplanned rehospitalization (hazard ratio, 1.49; 95% confidence in

178 0-4.43; P = .005) and composite of mortality/rehospitalization (HR, 2.35; 95% CI, 1.52-3.62; P < .001

179 for the placebo group (137 CV deaths, 224 HF rehospitalizations; HR, 0.93; 95% CI, 0.79-1.09; P = .36

180 rhea may lead to dehydration, malabsorption, rehospitalization, immunosuppression, noncompliance, and

181 found in reducing hospital use (for example, rehospitalizations), improvement of continuity of care (

182 among MP were respiratory problems, eczema, rehospitalization in infancy, passive smoking in infancy

183 analyzes showed the same results except for rehospitalization in infancy.

184 8 infants diagnosed with CHDs at birth or at rehospitalization in infancy; the overall CHD prevalence

185 he association between RPM use and all-cause rehospitalization in patients enrolled in Medicare fee-f

186 mpared with men, women are at higher risk of rehospitalization in the first month after discharge for

187 The absolute risk reductions of COPD-related rehospitalization in the health coaching group were 7.5%

188 Women have an increased risk of rehospitalization in the immediate postdischarge period;

189 calculate hospitalization rates and to model rehospitalization in the year after diagnosis, accountin

190 roup difference showing larger reductions in rehospitalizations in intervention communities (by 0.56/

191 g hospital discharge are estimated to reduce rehospitalizations in patients undergoing hemodialysis.

192 activity, prognostic biomarkers, and cardiac rehospitalizations in post-ACS patients.

193 heir primary language have a greater risk of rehospitalization, independent of clinical factors and r

194 in a prospective, 24-center US study who had rehospitalizations independently classified by experienc

195 Our primary outcome was unplanned rehospitalizations (inpatient or observation status) wit

196 Rehospitalization is a quality-of-care indicator, yet li

197 The risk of rehospitalization is about 20% to 30% lower during long-

198 ormation about long-term mortality, rates of rehospitalization, long-term morbidity, comparative effe

199 practice and Medicare payment penalties for rehospitalization may have confounded the results.

200 erm outcomes on the basis of 1-year risk for rehospitalization, mortality, or allograft failure/rejec

201 focusing on quality of life, cardiac events, rehospitalizations, mortality, and medical, behavioral,

202 alculated the (1) time required for adjusted rehospitalization/mortality risks to decline 50% from ma

203 ed an emergency department visit (n = 96), a rehospitalization (n = 38), or both (n = 24).

204 nical efficacy (ie, survival free of stroke, rehospitalization, New York Heart Association 3/4, and d

205 ncident MI (31.2% ST-segment elevation), 643 rehospitalizations occurred within 30 days in 561 (18.6%

206 Death or rehospitalization occurring within 2 days and by 30 days

207 se) was associated with lower odds of 30-day rehospitalization (odds ratio, 0.95; 95% confidence inte

208 Risk of rehospitalization of patients using RPM (n=9150, 60%) wa

209 ffer recurrent disease, which often requires rehospitalization of patients.

210 vascularization was performed in 103 (16.0%) rehospitalizations, of which 46 (44.7%) had no revascula

211 characteristics were associated with 30-day rehospitalization: older age, the number of hospital adm

212 ps did not differ in time-to-first all-cause rehospitalization or death or in mean numbers of rehospi

213 outcome of time to first heart failure (HF) rehospitalization or death.

214 cal outcomes defined as time to death, first rehospitalization or emergency department visit.

215 Randomization to UC + PAL did not affect rehospitalization or mortality.

216 spitalization or death or in mean numbers of rehospitalizations or deaths.

217 ith any increased risk for 1-year mortality, rehospitalization, or allograft failure/rejection.

218 ssociated with improvement in time to death, rehospitalization, or emergency department visit at 60 d

219 ore of 3-4), and the association with death, rehospitalization, or unscheduled medical visits through

220 se patients had lower 60-day rates of death, rehospitalization, or unscheduled visits (50%) compared

221 infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization

222 infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization.

223 month, and the combined endpoint of death or rehospitalization over 12 months was compared between gr

224 d quality of care and help to lower rates of rehospitalization overall and particularly among black a

225 but there are limited data describing their rehospitalization patterns and impact.

226 The mean rate of 30-day all-cause rehospitalizations per 1000 beneficiaries per quarter wa

227 primary outcome measure was all-cause 30-day rehospitalizations per 1000 Medicare FFS beneficiaries;

228 ssociated with lower risk of 30-day death or rehospitalization (per 10 patient increase: odds ratio,

229 and group 3=12.4%) and all-cause death plus rehospitalization potentially resulting from a cardiovas

230 ithin a disadvantaged U.S. neighborhood is a rehospitalization predictor of magnitude similar to chro

231 iation in hospital rates of 30-day unplanned rehospitalization ranged from 5.4% to 20.0%, with a medi

232 The 30-day rehospitalization rate did not vary significantly across

233 The 3-year all-cause rehospitalization rate in the Medicare population (n=15,

234 d 85% of neighborhoods, which had an average rehospitalization rate of 21%.

235 The overall 30-day rehospitalization rate was 21.2% (11959 of 56477 patient

236 0.33; log-rank P = .026), and reduced 30-day rehospitalization rates (16.9% vs 23.9%, P = .036).

237 fferences and factors associated with 1-year rehospitalization rates after AMI.

238 Rehospitalization rates for UA and unplanned revasculari

239 One-year crude all-cause rehospitalization rates for women were significantly hig

240 Recent mortality and rehospitalization rates in the Veterans Affairs Health C

241 the most disadvantaged 15% of neighborhoods, rehospitalization rates increased from 22% to 27% with w

242 bidity and mortality with current therapies, rehospitalization rates remain distressingly high, subst

243 Rehospitalization rates were significantly associated wi

244 Rehospitalization rates were significantly lower after d

245 ns to reduce rehospitalization that reported rehospitalization rates within 30 days.

246 on costs but decreased mortality and reduced rehospitalization rates.

247 s, with improved quality of life and reduced rehospitalization rates.

248 U and hospital stay, 6-month recurrence, and rehospitalization rates.

249 admitted yearly to an ICU, the frequency of rehospitalizations (readmissions to the hospital after d

250 y mediating the relationship between sex and rehospitalization remain unexplored and are needed to re

251 ardial infarction, unstable angina requiring rehospitalization, revascularization after 30 days, and

252 he most disadvantaged neighborhoods having a rehospitalization risk (adjusted risk ratio, 1.09 [95% C

253 rfusion are associated with increased 30-day rehospitalization risk after MI.

254 nding the determinants of sex differences in rehospitalization risk among conditions.

255 scularization were associated with increased rehospitalization risk.

256 Many rehospitalizations seem to be unrelated to the incident

257 1-year angina frequency and 1-year unplanned rehospitalization stratified by race and sex among MI pa

258 haracteristics were strongly associated with rehospitalization, suggesting that identifying high-risk

259 ant age-sex interaction was found for 1-year rehospitalization, suggesting that the increased risk ap

260 nd treatment failure (defined as psychiatric rehospitalization, suicide attempt, discontinuation or s

261 o identify factors associated with unplanned rehospitalization, testing for whether race and sex modi

262 ore-after studies of interventions to reduce rehospitalization that reported rehospitalization rates

263 ost-MI angina frequency and 1-year unplanned rehospitalization to identify factors associated with un

264 interaction between age and ICD treatment on rehospitalization (two-sided posterior tail probability

265 ions of PHQ-2 and PHQ-9 with both, death and rehospitalization, univariable Cox regression models wer

266 We compared sex differences in rehospitalization using a Cox proportional hazards model

267 identified factors associated with unplanned rehospitalizations using multivariable logistic regressi

268 The adjusted daily risk of rehospitalization varied by admitting condition (hazard

269 The effects of treatment on rehospitalization varied significantly over time.

270 ction, right heart failure, arrhythmias, and rehospitalizations varied greatly.

271 gh the association of sex with daily risk of rehospitalization varies across conditions, women are at

272 noncardiac comorbidities, mortality, stroke, rehospitalization, vascular complications, bleeding comp

273 s at a different hospital, 13.7% died during rehospitalization versus 11.1% who died at the index hos

274 At 2 years, the rate of rehospitalization was 35.0% in the TAVR group and 72.5%

275 The 30-day incidence of rehospitalization was 35.3% in patients who experienced

276 ted analyses, the composite of mortality and rehospitalization was similar for all subgroups.

277 The risk of psychiatric rehospitalization was the lowest during monotherapy with

278 tors most strongly associated with unplanned rehospitalization were baseline quality of life and depr

279 between neighborhood ADI grouping and 30-day rehospitalization were evaluated using multivariate logi

280 ar outcomes including mortality, stroke, and rehospitalization were evaluated using multivariate mode

281 Mortality and rehospitalization were examined using landmark analyses

282 Rates of 1-year unplanned rehospitalization were highest among black female patien

283 The most common causes of rehospitalization were ileus/obstruction and infection.

284 ompared with the VKA arm, but other forms of rehospitalization were not.

285 een baseline positive constructs and 6-month rehospitalizations were assessed via multivariable Cox r

286 lation, and all-cause and arrhythmia-related rehospitalizations were common.

287 rd ratios and cumulative incidence of 30-day rehospitalizations were determined by using Cox proporti

288 Overall, 30.2% of rehospitalizations were unrelated to the incident MI and

289 l (death, heart failure hospitalization, and rehospitalization) were generated, grouping patients by

290 tes mellitus were the most common reason for rehospitalization, whereas heart failure was the most co

291 ath, nonfatal myocardial infarction (MI), or rehospitalization with an acute coronary syndrome for an

292 Rehospitalization with myocardial infarction within 1 ye

293 ospital mortality, all-cause mortality or HF rehospitalization within 1 year, and in-hospital worseni

294 Rehospitalization within 30 days after an admission for

295 re than 5 days, institutional discharge, and rehospitalization within 30 days of discharge.

296 A similar pattern was observed for rehospitalization within 30 days, which occurred for 7.8

297 associated with 40% to 50% risk of death or rehospitalization within 6 months after discharge.

298 Factors associated with rehospitalization within both time periods were identifi

299 12 patients, 1326 (10.8%) had 1483 unplanned rehospitalizations within 30 days of the index event: 10

300 was the cumulative incidence of first early rehospitalization (within 30 days of discharge), and sec